

Sector View

Optical & Eyewear Sector

H2 should be better for all our sample even if the macro scenario limits visibility somewhat

	1 M	3 M	6 M	31/12/15
Consumer Gds	1.8%	4.2%	7.9%	-0.3%
DJ Stoxx 600	1.6%	2.6%	7.2%	-6.1%

*Stoxx Sector Indices

Companies covered

Company	Recommendation	Target Price
ESSILOR	BUY	EUR130
Last Price	EUR114,35	Market Cap. EUR24,939m
GRANDVISION	BUY	EUR28
Last Price	EUR26	Market Cap. EUR6,616m
LUXOTTICA	NEUTRAL	EUR54
Last Price	EUR43,46	Market Cap. EUR21,030m
SAFILO	NEUTRAL	EUR11
Last Price	EUR7,985	Market Cap. EUR500m

Although the Optical & Eyewear sector is very clearly enjoying structural catalysts and harbours significant growth potential over the MT-LT, sometimes our groups can be affected by temporary setbacks. In H1, the very poor performance in sunglasses (bad weather, slowdown in China) weighed on performances at both LUX and EI but we believe this was more temporary for the latter as the Italian group is also suffering from its “self-inflicted initiatives”. Its main competitor SFL posted a very good Q2 but visibility remains limited ahead of the Gucci transition at the end of 2016. Last but not least, sales & earnings momentum at GNVV clearly improved in Q2 and the group was the only player not to be affected by internal or external headwinds. As such, we should remain picky within our sample over the remainder of the year.

ANALYSIS

- Where the sun did not shine in Q2: North America...** The sunglass category was hit particularly harshly by adverse weather conditions, affecting EI's own brand portfolio (FGX and Costa that was still positive) and sales of sun lenses. LUX was also naturally impacted by the poor sun peak season, especially since the Group implemented painful initiatives that have hampered growth (see next page). In this difficult context it is interesting to note that SFL's wholesale business performed quite well with 7.6% adj. FX-n, notably driven by a robust growth with department stores. The **sport sunglass brands** (Oakley, Costa and Smith) had a difficult time with sporting goods retailers, as highlighted by the bankruptcy of Sports Authority (450 stores). Besides this weather effect, the **sun specialty retail chains** faced a lack of traction in tourist areas but **Sunglass Hut** (LUX) managed to rebound slightly in Q2 with SSSG of 0.5% vs. -1.3% in Q1, whilst **Solstice** (SFL) declined 18.2% as 11 stores were closed (to a total of 118 DOS).
- ... and Greater China (particularly H-K/Macau).** After a difficult start to the year, with sales down 33% due to implementation of the ARTEMIS inventory management, **Bolon** (EI) achieved a lower-than-expected rebound in Q2 given a softer Chinese sunglass market. LUX revenue decelerated in China vs. Q1 but remained in positive territory thanks to the price adjustments implemented in Q3 2015. This slowdown was mainly caused by a shift in the distribution model (i.e. from independent distributors to own distribution), causing some sales disruption. On the positive side, the optical business was well-oriented for both EI and LUX in Mainland China, but was still down in double-digits for the Italian group in H-K/Macau, which was also a drag on SFL's performance in the region (-27.3% FX-n).
- Europe and LatAm were robust for all our sample.** Indeed, EI achieved 4.5% LFL growth in **Europe**, representing the fifth consecutive quarter of growth above 4% (vs. MT target: 0-1%). This sound performance was a clear illustration of the successful combination of incremental marketing expense and innovation (Eyezen had a strong launch). **GrandVision**, which has the highest exposure to Europe within our sample (~89% of sales) posted SSSG of 3.6% vs. 0.9% in Q1, largely driven by an acceleration in Western Europe (“G4”: +3.2% vs. 0.3%) and in Northern/Central Europe (“Other Europe”: +2.1% vs. -0.5%). LUX achieved 5% FX-n with double-digit growth in Spain, Italy and Turkey, while SFL recorded an impressive 13.2% FX-n driven by increases above 10% in key markets such as Italy, Germany, France and the UK.
- Latin America: EI (+11.4% LFL)** even accelerated in Brazil, sales were up mid single-digit (vs. low single-digit in Q1) thanks to its multi-channel strategy (successful roll-out of mid-tier Kodak brand) and media push. Revenue in Argentina, Colombia and Mexico soared above 20%. **GNVV** also experienced robust trends in the region, with comparable growth in double digits, driven by Mexico. LUX posted 12.9% FX-n growth in the region with increases above 20% in Brazil and Mexico, while comps at **GMO** (optical retailer owned by LUX) increased high single-digit. SFL also returned to positive territory in Latin America.

Organic growth by region (GrandVision: comparable growth):

LFL growth (%)	North America		Europe		Asia-Pacific		Latin America		ROW / Other	
	Q2	H1	Q2	H1	Q2	H1	Q2	H1	Q2	H1
Essilor (Lenses only)	1.5	3.1	4.5	4.6	8.5	8.7	11.4	10.3	-1.5 *	-5.8 *
GrandVision **	n/a	n/a	3.2/2.1	1.8/0.8	Americas & Asia: 9.7 and 9.2		n/a	n/a	n/a	n/a
Luxottica	-0.3	0.5	5.0	4.7	0.5	-0.7	12.9	13.0	-7.0	-7.6
Safilo	-1.2	-3.4	13.2	6.1	-27.3	-27.8	ROW incl. LatAm: 9.5 and 2.0			

* = Readers & Sun / ** Europe = G4 and Other Europe respectively

Source: Company Data, BG



- H1: margin contraction for everyone, GrandVision excepted.** EI's contribution margin narrowed 20bp to 18.9% as efficiency gains and a positive product-mix were offset by the poor performance of Transitions in the US, higher marketing expenses and M&A, but remains in line with the FY target ("at least 18.8%" vs. 18.8% achieved in 2015). **GVNV** benefited from a better SSSG (op. leverage) and a positive product-mix, driven by a higher share of exclusive brand frames (+10pp to ~70%) and fewer sunglass sales (less profitable). Hence adj. EBITDA margin improved 20bp to 16.3% (+60bp to 16.7% excl. M&A). **LUX's** adj. EBIT margin narrowed 30bp to 18.2%, which was quite satisfactory in our view given the poor sun season and weak FX-n growth in H1 (+1.6% vs. 3% required for a positive op. leverage) and the numerous self-inflicted initiatives. These headwinds were partly offset by efficiency gains and tight cost control (opex: -100bp). **SFL's** adj. EBITDA margin was only down 40bp to 8.9% thanks to a 90bp-improvement in Q2. This rebound was entirely derived from cost-cutting measures and positive operating leverage (opex costs: -160bp), offsetting the negative product-mix implied by the Gucci transition.

VALUATION

- As most of the groups in our sample were affected by a more difficult macro environment as well as "company-specific" setbacks, it is important that we try to assess the tipping point towards more favourable sales/earnings momentum:

1/ GrandVision was the only group to post better-than-expected H1 results thanks a strong second quarter, fuelled by the group's growth pillars (exclusive brand portfolio, competitive offering, store openings) whilst the profitability continued to improve despite the dilutive impact from M&A. This favourable momentum bodes well for H2, especially since comparison bases will become easier (SSSG of 2.9% in H2 15 vs. +5.2% in H1). **Hence GNVV would be our safest choice at this stage.**

2/ Essilor: we believe that the **factors behind weak LFL growth in Q2 were temporary** and expect actions within Transitions and the R&S division (Bolon and Costa: geographical expansion, travel retail) to drive the rebound in H2. The further integration of the alliance groups (fast-growing channel), should also fuel LFL growth in North America from Q3. The lower FY sales target still implies 5% growth over H2, **confirming that a rebound could take place as early as Q3.**

3/ Luxottica: we feel that **LUX suffered particularly from its initiatives** (MAP, Oakley integration, etc.) as the group performed quite well in Europe/LatAm where no actions were initiated. These initiatives were eventually more painful and complicated to implement given more challenging business and macro conditions. Even if the new FY sales guidance implies a slight acceleration in H2 (~+3%e adj. FX-n vs. +1.6% in H1), **visibility is limited in the ST.**

4/ Safilo: The **first positive results** of the longstanding actions implemented over the last two years are emerging, as highlighted by the Q2 performance. However, the **Gucci transition** remains a key issue for H2 (~16-17% of sales), as well as the **underperformance of its own brands.** If SFL handles the transition as efficiently as Georgio Armani in H2 2012, it could reassure investors and provide a key catalyst for the stock. In the meantime, **visibility is also limited in the ST.**

Our general overview for our Optical & Eyewear sample:

Company	(i) Q2 Organic Growth	(ii) H1-Results Performance	(iii) FY16 Outlook	Comments
Essilor				(i): 3.2% LFL growth miss (CS: +5%) vs. +5% in Q1 due to a poor performance in photochromic (Transitions) and sun lenses (ii): CM: -20bp to 18.9% (CS: 19%) but it is consistent with FY guidance ("at least 18.8%" vs. 18.8% achieved in 2015). (iii): FY16 LFL growth target was slightly revised down to "~4.5%" vs. "~5%" because of the Q2 miss, it does not imply any slowdown in H2 (+5%), FY CM target was maintained.
GrandVision				(i): Comparable growth of 3.6% (CS: +2.3%) vs. 0.9% in Q1, all three regions have accelerated (ii): Adj. EBITDA margin up 20bp to 16.3% (+60bp excl. M&A), driven by a favourable product-mix, efficiency gains and a positive op. leverage (iii): No FY guidance but MT targets were confirmed (sales up >+5% FX-n and adj. EBITDA growth in the high single-digits)
Luxottica				(i): Adj. FX-n sales growth slightly decelerated to 1.4% vs. 1.8%, dented by Group's own initiatives and the weak sun peak season (ii): Adj. EBIT margin down 30bp to 18.2% as efficiency gains and a tight cost control have partly offset the margin headwinds (iii): Lowered FY16 targets: FX-n growth of 2-3% (= => +3%e in H2) vs. +5-6 previously and adj. EBIT growth: 1x sales growth vs. 1.5x initially
Safilo				(i): Sharp acceleration of the "going-forward PF" with +9% vs. +1% in Q1 that was affected by production bottlenecks (ii): Adj. EBITDA margin down 40bp to 8.9%, the Gucci transition was almost offset by cost-cutting measures and a positive op. leverage (iii): No FY targets but management is "reasonably optimistic" about H2 even if the Gucci transition limits the visibility

[Click here to download document](#)



Analyst:
Cédric Rossi
33(0) 1 70 36 57 25
crossi@bryangarnier.com

Consumer Analyst Team:
Nikolaas Faes / Virginie Roumage
Loïc Morvan
Antoine Parison

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55,7%

NEUTRAL ratings 32,9%

SELL ratings 11,4%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	Tel +91 11 4132 6062
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	+91 98 1111 5119
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Fax +91 11 2621 9062
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			Geneva
Financial Conduct Authority (FCA)	Autorité de Contrôle prudentiel et de			rue de Grenus 7
	resolution (ACPR)			CP 2113
				Genève 1, CH 1211
				Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..